Recent research indicates that low-density neutrophils, such as low-density granulocytes, exert proinflammatory effects on the T cells of SLE patients. In the study, researchers confirmed SLE patients had a higher prevalence of low-density granulocytes than healthy controls and that these cells appeared to promote a Th1 response…
Metabolic Profiling of SLE
Research examining the metabolic profile of SLE found increased oxidative activity, as well as lower levels of tyrosine and tryptophan, in SLE patients relative to controls, suggesting increased activity of aromatic amino acid decarboxylase. The results suggest metabolomics may have the ability to measure disease severity in SLE…
History of Depression Is a Risk Factor for SLE in Women
Results from a 20-year, cohort study add to the evidence that depression increases the risk of developing an autoimmune disease, specifically SLE in women. Lead investigator Andrea Roberts, PhD, says, “There may be direct biological effects of depression that increase the risk of autoimmune disease.”…
Alterations in Macrophage Activation May Signal a Lupus Flare
New data suggest myeloid cells in SLE patients skew B and T cell activation status toward the M1 proinflammatory phenotype, thereby directing SLE flares and remission…
Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE
Patients who develop neuropsychiatric symptoms of SLE have a small nucleotide polymorphism (SNP) in an intron in a Ca++ ion channel gene that influences some, but not all, events regulated by Ca++. The SNP appears to influence activation induced apoptosis rates and cytokine production, specifically IL-4, in a disease- and genotype-specific manner…
Physical & Cognitive Function in SLE Patients
New research used multidomain function assessment to better understand the physical and cognitive functioning of systemic lupus erythematosus (SLE) patients. The pilot study found a high prevalence of impairment in SLE patients, similar to or exceeding the prevalence seen in the general geriatric population. Patients scored lower for lower body strength and low average for cognitive flexibility and attention…
Results from Belimumab Safety Study
In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation
Does cognitive dysfunction in SLE patients result from persistent inflammation characterized by ongoing disease activity? Recent research examining this question found no inflammatory mechanism associated with cognitive dysfunction in this patient population, underscoring previous research findings…
Insight into the Downregulation of NK Cells in SLE Patients
New research suggests the downregulation of CD3ζ contributes to the altered function of NK cells in SLE patients, which may contribute to the increased risk of viral infections in these patients…
Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »